AMR

R&D

Europe has the tools to fight superbugs. Let’s use them.

Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.

R&D

Why conditions like UTI call for new antibiotics

Exploring the growing threat of UTIs, the need for new antibiotics, and GSK’s role in advancing targeted treatments.

R&D

Why I'm focused on the trillion-dollar AMR crisis everyone's...

AMR demands sustained commitment beyond conventional market incentives.

R&D

When is the superbug message going to bite?

As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.

News

Roche takes new antibiotic into phase 3 for 'urgent threat'

Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance.

R&D

Growing threat of AMR: UN calls for urgent global action

In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c

Europe has the tools to fight superbugs. Let’s use them.

Why conditions like UTI call for new antibiotics

Why I'm focused on the trillion-dollar AMR crisis everyone's...

When is the superbug message going to bite?

Roche takes new antibiotic into phase 3 for 'urgent threat'

Growing threat of AMR: UN calls for urgent global action

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

AMR

Editor's Picks